In the US 40,000 People Died From Metastatic Breast Cancer in 2003, With Median Survival Rates Estimated to Be Two Years
Posted on: Friday, 18 November 2005, 12:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c27949 ) has announced the addition of Profiles in Metastatic Breast Cancer to their offering.
In 2003, approximately 40,000 deaths in the United States were attributed to breast cancer. While significant therapeutic advances for early-stage disease have emerged in recent years, an estimated 30% to 40% of all patients (in Western countries) ultimately develop metastatic breast cancer (MBC). Median survival for MBC patients is estimated at an all too brief two years, underscoring tremendous unmet need among the MBC population.
Profiles in Metastatic Breast Cancer spotlights for drug developers potential opportunities for clinical and commercial advances in MBC drug development. These potential opportunities are identified through insights derived from:
A qualitative online discussion among key opinion leaders
A quantitative survey and conjoint exercise completed by 100 community-based oncologists in the United States
This study will help clients understand therapeutic unmet needs and the product attributes and levels of performance that drive physician preference and prescribing behavior. Further, the study looks prospectively at promising novel therapeutic targets and investigational agents for MBC. Taken together, the components of Profiles in Metastatic Breast Cancer form an essential analytical tool for any organization contemplating the development, acquisition, or launch of an agent aimed at this vastly underserved patient population.
Key Points:
1. While community oncologists and KOLs provided similar responses in ranking toxicities from the physician perspective, the two groups diverged noticeably in ranking toxicities from the patient perspective
2. Although one of the longstanding assumptions of drug development is that oral administration is almost always preferable to IV/injectable administration, a tradeoff analysis among a large body of practicing oncologists here reveals that oral administration is of minimal importance
For more information visit http://www.researchandmarkets.com/reports/c27949
Source: Business Wire
Related Articles
- Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer
- Avastin's Use in Treatment of Metastatic Breast Cancer Expected to Increase Dramatically on Heels of FDA's Accelerated Approval, According to Study By GfK Market Measures
- New Survey Underscores Importance of Psychosocial and Educational Needs Among Women With Advanced Breast Cancer
- Early Diagnosis and Targeted Therapy to Address Unmet Need in European Breast Cancer Therapeutics Market
- Breast Cancer Risk Dramatically Reduced With Osteoporosis Drug
- UK breast cancer sufferer goes to court for drug
- Genesis Bioventures Announces Breast Cancer Marker Receives Diagnostic and Therapeutic Patent Approval
- Ulster Breast Cancer Patient in Battle for Wonder Drug
- Breast Cancer Survival Hopes Boosted By New Drug on NHS
- Breast Cancer Prevention Study Spotlights Debate Over Drug Trials
 |
 |
User Comments (0)
RSS Feeds